We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NHS England has announced that from April this year it will fund Novartis' Afinitor (everolimus) for patients living with Tuberous Sclerosis Complex (TSC)-related refractory epilepsy.
Decision marks the third TSC-related indication for Votubia in the EU.Novartis has announced that the European Commission has approved Votubia (everolimus) dispersible tablets as an adjunctive treatment...